

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/729,222 (Conf #9553)
Filing Date	5 December 2003
First Named Inventor	Peter G. KLIMKO, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2443 US

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
zrf	A1	US- 5,075,116	12/24/1991	Lahaye et al.	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	A20					
	A21					
	A22					
	A23					
	A24					
	A25					

Examiner
Signature

zrf

Date
Considered

7/26/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, 400 ...
 No response is required to this notice unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Complete If Known

Application Number	10/729,222 (Conf #9553)
--------------------	-------------------------

Filing Date	5 December 2003
--------------------	-----------------

First Named Inventor	Peter G. KLIMKO et al.
----------------------	------------------------

Art Unit	1614
----------	------

Examiner Name

Attorney Docket Number	2443 US
------------------------	---------

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

zahl Fr

Date
Considered

7126108


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/729,222 (Conf #9553)
Filing Date	5 December 2003
First Named Inventor	Peter G. KLIMKO et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	2443 US

Sheet 1 of 3

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
2-F	A1	US-	5,994,339	11/30/1999	Crapo et al.	
2-F	A2	US-	6,127,356	10/03/2000	Crapo et al.	
2-F	A3	US-	6,177,419	01/23/2001	Campbell et al.	
2-F	A4	US-	6,180,620	01/30/2001	Salvemini	
2-F	A5	US-	6,214,817	04/10/2001	Riley et al.	
2-F	A6	US-	6,541,490	04/01/2003	Campbell et al.	
	A7	US-				
	A8	US-				
	A9	US-				
	A10	US-				
	A11	US-				
	A12	US-				
	A13	US-				
	A14	US-				
	A15	US-				
	A16	US-				
	A17	US-				
	A18	US-				
	A19	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
2-F	A20	WO 98/58636 A1 and A2		12/30/1998	G.D. Searle		
2-F	A21	WO 00/07584 A2 and A3		02/17/2000	Wisconsin Alumni		
2-F	A22	WO 00/19993 A2 and A3		04/13/2000	Brownlee		
2-F	A23	WO 00/72893 A2 and A3		12/07/2000	Monsanto Co.		
2-F	A24						
	A25						

Examiner
SignatureDate
Considered

7/26/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/729,222 (Conf #9553)		
		Filing Date	5 December 2003		
		First Named Inventor	Peter G. KLIMKO et al.		
		Art Unit	1614		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	2443 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Z. f	B1	Allikmets R, et al., "Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration", Science, 277:1805-1807 (1997). Listed as "Dean" in application.	
Z. f	B2	Baker et. al., "Synthetic Combined Superoxide Dismutase/Catalase Mimetics Are Protective as a Delayed Treatment in a Rat Stroke Model: A Key Role for Reactive Oxygen Species in Ischemic Brain", J. Pharmacol. Exp. Ther., Vol. 284:215-221, 1998	
Z. f	B3	Ben-Shabat et al., "Fluorescent Pigments of the Retinal Pigment Epithelium and Age-Related Macular Degeneration", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 11:1533-1540, 2001. Listed as "Nakanishi" in application.	
Z. f	B4	Brownlee, M., "Biochemistry and Molecular Cell Biology of Diabetic Complications", Nature, Vol. 414:813-820, 2001	
Z. f	B5	Coppey, et al., "Effect of M40403 Treatment of Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity and Vascular Function of Epineurial Arterioles of the Sciatic Nerve," British Journal of Pharmacology, Vol. 134:21-9, 2001 (M40403)	
Z. f	B6	Doctrow et. al., "Salen-Manganese Complexes as Catalytic Scavengers of Hydrogen Peroxide and Cytoprotective Agents: Structure-Activity Relationship Studies", J. Med. Chem., 45:4549-4558 (2002)	
Z. f	B7	Görlér, et al., "The Role of Oxidative Stress in Diabetic Retinopathy" Eye, Vol. 14:730-735, 2000	
Z. f	B8	Guzik, et al., "Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus" Circulation, Vol. 105:1656-62, 2002	
Z. f	B9	Kimura K et al., "Genetic Association of Manganese Superoxide Dismutase With Exudative Age-related Macular Degeneration", AMERICAN JOURNAL OF OPHTHALMOLOGY, 130(6):769-773 (2000). Listed as "Isashiki" in the application.	
Z. f	B10	Mata NL et al., "Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration", Proc. Natl. Acad. Sci. USA, 97(13):7154-7159 (2000). Listed as "Travis" in the application.	

Examiner Signature	<i>Zahid Foz</i>	Date Considered	7/26/05
--------------------	------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/729,222 (Conf #9553)		
		Filing Date	5 December 2003		
		First Named Inventor	Peter G. KLIMKO et al.		
		Art Unit	1614		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	2443 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2.f	C1	Melov et. al., "Lifespan Extension and Rescue of Spongiform Encephalopathy in Superoxide Dismutase 2 Nullizygous Mice Treated with Superoxide Dismutase-Catalase Mimetics", J. Neurosci., Vol. 21:8348-8353, 2001	
2.f	C2	Parish et al. (Nakanishi), "Isolation and one-step preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium", Proc. Natl. Acad. Sci. USA, 95:14609-14613, 1998	
2.f	C3	Piganelli, et al., "A Metalloporphyrin-Based Superoxide Dismutase Mimic Inhibits Adoptive Transfer of Autoimmune Diabetes by a Diabetogenic T-cell Clone," Diabetes, Vol. 51:347-55, 2002	
2.f	C4	Salvemini D, et. al., "A Nonpeptidyl Mimic of Superoxide Dismutase with Therapeutic Activity in Rats", Science, Vol. 286:304-306, 1999	
2.f	C5	Shamsi and Boulton, "Inhibition of RPE Lysosomal and Antioxidant Activity by the Age Pigment Lipofuscin", Invest. Ophthalmol. Vis. Sci., Vol. 42:3041-3046, 2001	
2.f	C6	Shurtz-Swirski et al., "Involvement of Peripheral Polymorphonuclear Leukocytes in Oxidative Stress and Inflammation in Type 2 Diabetic Patients," Diabetes Care, Vol. 24:104-110, 2001	
2.f	C7	Wang et. al., "Tempol, A Superoxide Dismutase Mimic, Ameliorates Light-Induced Retinal Degeneration", Res. Commun. Mol. Pathol. Pharmacol., 89(3):291-305, 1995	
2.f	C8	Wassell et al., "The Photoactivity of the Retinal Age Pigment Lipofuscin", J. Biol. Chem., 274:23828-23832, 1999	
2.f	C9	Wihlmark et. al., "Lipofuscin Accumulation In Cultured Retinal Pigment Epithelial Cells Causes Enhanced Sensitivity To Blue Light Irradiation", Free Radical Biol. Med., 22:1229-1234, 1997	
2.f	C10	Winkler, et. al., "Oxidative damage and age-related macular degeneration", Mol. Vision, Vol. 5:32, 1999	

Examiner Signature		Date Considered	7/26/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.